Boston, May 16, 2004 - Data presented today at a top U.S. transplant meeting demonstrated better patient and graft (organ) survival in liver and kidney transplant patients taking CellCept® ...

Data presented today at the International Society for Heart and Lung Transplantation (ISHLT) annual meeting strengthens the body of evidence that CellCept (mycophenolate mofetil, MMF) has unique ...

CellCept (mycophenolate mofetil) is a prescription drug that helps prevent organ rejection after certain organ transplants. CellCept can interact with other medications and some supplements. For ...

Please provide your email address to receive an email when new articles are posted on . Patients with systemic lupus erythematosus who withdrew had an 18% risk for disease reactivation vs. 11% among ...

CellCept (mycophenolate mofetil) is a brand-name drug that’s prescribed to help prevent organ rejection after a transplant in adults and some children. CellCept comes in several forms. The dosage can ...

CellCept (mycophenolate mofetil) is a brand-name drug that’s prescribed to prevent organ rejection after certain organ transplants. CellCept has interactions with some other drugs and supplements. An ...

Please provide your email address to receive an email when new articles are posted on . Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves ...

CellCept (mycophenolate mofetil) is a prescription drug used to prevent organ rejection after certain organ transplants. CellCept’s cost may depend on factors such as your dosage, whether you have ...

Rituximab and mycophenolate mofetil are used to treat pemphigus vulgaris, but they have not been adequately compared in clinical trials. In a randomized, controlled trial, we assigned patients with ...